Abstract P151 Table 1

Clinical and serological characteristics

ItemsAll patients (N=65)MS (N=32)DAF (N=22)
Acute cutaneous lupus, n (%) 40 (61.5) 21 (65.6) 10 (45.4)
Chronic cutaneous lupus, n (%) 1 (1.5) 1 (3.1) 0 (0)
Malar erythema, n (%) 25 (38.5) 13 (40.6) 6 (27.3)
Photosensitivity, n (%) 35 (53.8) 17 (53.1) 9 (40.9)
Arthritis, n (%) 56 (86.2) 17 (53.1) 18 (81.8)
Non-scarring alopecia, n (%) 21 (32.3) 7 (31.8) 9 (40.9)
Oral/nasal ulcers, n (%) 14 (21.5) 8 (25) 5 (22.7)
Serositis, n (%) 2 (3.1) 0 (0) 0 (0)
Nephritis, n (%) 1 (1.5) 1 (3.1) 0 (0)
Leukopenia, n (%) 11 (16.9) 6 (18.8) 3 (13.6)
Thrombocytopenia, n (%) 2 (3.1) 1 (3.1) 0 (0)
Cranial neuropathy (other than optic nerve), n (%) 12 (18.5) 6 (18.8) 1 (4.5)
Seizures, n(%) 2 (3.1) 1 (3.1) 4 (18.2)
Fever, n(%) 7 (10.8) 4 (12.5) 1 (4.5)
Sicca, n(%) 14 (21.5) 11 (34.4) 1 (4.5)
Raynaud’s, n(%) 18 (27.7) 9 (28.1) 5 (22.7)
Livedo reticularis, n(%) 6 (9.2) 3 (9.4) 2 (9.1)
Antinuclear antibodies (ANA), n(%) 49 (75.4) 23 (71.9) 17 (77.3)
Anti-dsDNA, n(%) 5 (7.7) 1 (3.1) 1 (4.5)
Low complement, n(%) (C3/C4) 13 (20) 4 (12.5) 3 (13.6)
Anti-SSA, n(%) 10 (15.4) 5 (15.6) 4 (18.2)
Anti-SSB, n(%) 5 (7.7) 2 (6.3) 1 (4.5)
Anti-RNP, n(%) 3 (4.6) 2 (6.3) 1 (4.5)
Antiphospholipids antibodies (aPL), n(%) 11 (16.9) 6 (18.8) 4 (18.2)
CSF presence of oligoclonal bands, n(%) 20 (30.8) 18 (56.3) 1 (4.5)
CSF positive IgG index, n(%) 36 (55.4) 17 (53.1) 6 (27.3)